Meta-Analysis of Cytochrome P-450 2C9 Polymorphism and Colorectal Cancer Risk

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Liang, Shuo ^a   Hu, Jingsong ^b   Cao, Weijun ^a   Cai, Sanjun ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; ASIAN; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CHINESE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CYP2C9 GENE; DOMINANT GENE; ETHNICITY; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; HISPANIC; HUMAN; RECESSIVE GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CHINA; COLORECTAL NEOPLASMS; ETHNIC GROUPS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84868698174     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049134     Document Type: Article

References (34)

1. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378.
2. Gertig DM, Hunter DJ, (1998) Genes and environment in the etiology of colorectal cancer. Semin Cancer Biol 8: 285-298.
3. Marchand LL, (1999) Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. J Natl Cancer Inst Monogr 26: 101-105.
4. Lafuente MJ, Casterad X, Trias M, et al. (2000) NAD(P)H:quinone oxidor-eductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 21: 1813-1819.
5. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME, (1997) The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 376: 153-160.
6. Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, Minchin RF, (1994) Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 47: 914-917.
7. Goldstein JA, De Morais SM, (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299.
8. Inoue K, Yamakazi H, Imiya K, Akasaka S, Guengerich FP, Shimada T, (1997) Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113.
9. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD, (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293: 453-459.
10. Tang C, Shou M, Rodrigues AD, (2000) Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity. Drug Metab Dispos 28: 567-572.
11. Tang C, Shou M, Rushmore TH, et al. (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmaco-kinetics. Pharmacogenetics 11: 223-235.
12. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E, (2002) Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 54: 423-429.
13. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K, (2000) CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 10: 95-104.
14. Crespi CL, Miller VP, (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 7: 203-210.
15. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
16. Woolf B, (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251-253.
17. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
18. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-101.
19. Martinez C, Garcia-Martin E, Ladero JM, Sastre J, Garcia-Gamito F, et al. (2001) Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22: 1323-1326.
20. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS, (2004) A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2: 704-712.
21. Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, et al. (2005) Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Mol Carcinog 44: 21-30.
22. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, et al. (2005) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15: 535-546.
23. McGreavey LE, Turner F, Smith G, Boylan K, Timothy Bishop D, et al. (2005) No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 15: 713-721.
24. Samowitz WS, Wolff RK, Curtin K, Sweeney C, Ma KN, et al. (2006) Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol 4: 894-901.
25. Liao LH, Zhang H, Lai MP, Lau KW, Lai AK, et al. (2007) The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta 380: 191-196.
26. Küry S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, et al. (2007) Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev 16: 1460-1467.
27. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, et al. (2008) Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 3098-3107.
28. Buyukdogan M, Boruban MC, Artac M, Demirel S, (2009) Frequency of Cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carcinoma. Int J Hemato Oncol 19: 134-139.
29. Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, et al. (2010) Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20: 315-326.
30. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P, (2010) Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 172: 1000-1014.
31. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, et al. (2011) Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 18: 265-276.
32. Xiong Y, Wang M, Fang K, Xing Q, Feng G, Shen L, He L, Qin S, (2011) A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. Genomics 97: 277-281.
33. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al. (1998) Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8: 365-373.
34. Zhou SF, Zhou ZW, Yang LP, Cai JP, (2009) Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16: 3480-3675.